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OBJECTIVES: To investigate the variation in resource
utilization and treatment costs for moderate to severe RA
patients in ﬁve countries (Australia, Canada, France,
Germany, UK). METHODS: Resource utilization was
collected alongside a 6-month multinational phase-III
clinical trial assessing the safety and efﬁcacy of Adali-
mumab (D2E7), a fully human anti-TNF antibody,
among 325 established RA patients who failed previously
3.7 DMARDs and had a 11-year mean disease duration
(DE011/DE026). Data on 54 resource utilization items
were collected including direct costs (e.g. hospitalizations,
procedures, medications); direct non-medical costs (e.g.
transportation, devices), and indirect costs (e.g. produc-
tivity loss, family support) during 12 months of living
with RA. Resources were valuated using country-speciﬁc
prices and standardized to 2001US$. A human-capital
approach was employed to estimate productivity losses.
RESULTS: Mean societal total cost was US$7174
(SEM471) per patient across all countries. However sig-
niﬁcant variation existed at the country-level. The UK 
had the highest societal total cost: US$9277 (SEM1876)
followed by France US$9275 (SEM1155), Germany
US$7448 (SEM951), Canada US$6347 (SEM855) and
Australia US$5174 (SEM711). 95% of total costs were
explained by direct costs in the UK compared to 70% in
Germany, where lost productivity was a larger factor. Of
direct costs, hospital inpatient costs contributed almost
44.5% (Germany), 40.3% (UK), 36.9% (Australia),
33.5% (France) and 13.1% (Canada). Medical to non-
medical direct cost ratios varied from 1 :1 in Australia to
almost 1 :2 in the UK. CONCLUSIONS: These results are
consistent with the mean cost of US$6270 estimated from
a systematic review of 11 US and 4 European studies
(Cooper, Rheumatology 2000). Treatment costs are 2.5
times greater in this study of longstanding severe RA
patients than in published studies of early RA patients.
This study provides a comprehensive picture of health-
care services used for the treatment of RA patients and
indicates that pronounced country differences exist.
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OBJECTIVES: COX-2 inhibitors (COXIBs) have been
introduced in Italy in September 2000. We investigated
and identiﬁed differences in history of claims for 
gastrointestinal disorders (GIDs) between COXIBs vs
NSAIDs patients. METHODS: Prescriptions of antin-
ﬂammatories made by 200GPs to a population of 24,428
arthritis patients in a Northern Italian area were retro-
spectively investigated, focused on the ﬁrst six months 
of COXIBs availability (1st October 2000–31st March
2001). COXIBs were prescribed to 6,204 patients and
NSAIDs to 18,224 patients. We extracted the data of 
all 442 COXIB patients who received a co-prescription
(i.e.simultaneously prescribed at least once in the obser-
vation period) of a gastroprotective agent (GPA). COXIB
+ GPAs patients were compared to a sample of 442
NSAIDs + GPAs patients, matched for age and gender.
The two groups were compared in terms of history of
claims for GIDs, including GPA prescription, diagnostic
procedures, and hospitalizations, occurred in the course
of the previous 2 years (1st October 1998–30th Septem-
ber 2000). Reimbursed prices, for drugs, and tariffs paid
by NHS, for procedures and hospitalizations, were used
to calculate costs. RESULTS: Prior to starting their COX-
2 treatment, 84% of COXIB + GPAs patients vs 79% of
NSAIDs + GPAs patients had a history of GID with sig-
niﬁcantly higher (p = .0026, U test) mean costs (€554.9
vs €362.6). All cost items were higher in the former
group: hospitalizations (€185.8 vs 76.8), procedures
(€52.5 vs 43.2), GPAs (€316.6 vs 242.6). CONCLU-
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SIONS: Patients starting a treatment with COXIBs +
GPAs are likely to have a previous history of GIDs sig-
niﬁcantly more severe and costly than patients who 
continue NSAIDs + GPAs. This constitutes a confound-
ing factor when assessing therapy effectiveness and safety,
in particular when evaluating co-prescription rates with
GPAs in patients treated with antinﬂammatories.
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OBJECTIVES: To focus on the Bulgarian market of M01
group for the period 1999–2001; the most consumptive
active principles (APs) within M01; to determine the
trend in M01 consumption and within. METHODS:
M01 consumption at national level has been calculated
by ATC/DDD methodology and expressed in
DDD/1000/day. Data have been collected from: a) the
import of wholesalers, b) the local industry sale reports
for the domestic market. Comparison has been made with
M01 consumption in Norway and Sweden (expressed 
in DDD/1000/day). RESULTS: M01 consumption at
national level has been calculated as follows: 1999—
14,216; 2000—13,764; and 2001—15,565. The most
consumptive APs within M01 were: Diclofenac (D)
1999—8,448; 2000—8,728; and 2001—9,753; Piroxi-
cam (P) 1999—3,380; 2000—2,892; and 2001—2,761;
Indometacin (Ind) 1999—1,457; 2000—1,061; and
2001—1,104; Ketoprofen (K) 1999—0,192; 2000—
0,439; and 2001—0,699; Tenoxicam (T) 1999—0,598;
2000—0,172; and 2001—0,699. Ibuprofen (Ib) con-
sumption was: 1999—0,169; 2000—0,030; and 2001—
0. The coxib Rofecoxib (R) consumption was registered
initially in 2001—0,054. CONCLUSIONS: M01 con-
sumption 1999–2001 did not show signiﬁcant variations.
The national demand for M01 is approximately 14
DDD/1000/day. M01 consumption in Norway and
Sweden was higher. D as the most consumptive AP at a
national level was about 67% of M01 consumption due
to 4 locally produced products. Dynamics within the
group was: D and K increased slightly; Ind showed rela-
tively steady-state position; P slightly decreased; the trend
in T consumption could not be deﬁned distinctly; Ib
decreased in consumption; Coxibs were with limited
place within M01. In comparison with Bulgaria, M01
consumption model in Norway and Sweden showed some
differences.
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OBJECTIVES: Osteoporosis, breast cancer and cardio-
vascular diseases are the main health problems among
postmenopausal women. We aimed to compare the cost-
effectiveness of raloxifene, alendronate or nasal calcitonin
in postmenopausal women, taking into account available
evidence for their preventive effect on a hip, vertebral,
wrist and ankle fractures, breast cancer, stroke and
myocardial infarction risk. METHODS: Markov model
was constructed to perform CEA and CUA over three
years from a health-care payers perspective, based on
Polish data on health-care resource utilisation and unit
cost. Treatment efﬁcacy and utility were derived from the
literature. Target population were patients aged 60–70,
without (group I) and with or without (group II) previ-
ous vertebral fracture. The outcomes measures were LYG
and QALYs gained, calculated on the basis of available
evidence for a preventive effect on an osteoporotic frac-
tures, breast cancer and cardiovascular events risk. The
cost-effectiveness threshold was calculated on basis of 1-
year haemodialysis treatment cost (60000 PLN, 1 USD =
4 PLN). The one-way and two-way sensitivity analysis
were performed. RESULTS: The highest effectiveness in
terms of LYG and QALYs was achieved with raloxifene
treatment, calcitonin was the least effective and the most
costly strategy. Incremental analysis suggests, that ralox-
ifene compared to alendronate was cost-effective: the
ICER was 15,975 PLN/LYG and 14,039 PLN/QALY
gained in group I, and 20,730 PLN/LYG and 17,915
PLN/QALY gained in group II. Sensitivity analyses
demonstrated robustness of the results in all cases calci-
tonin remained dominated strategy and ICER raloxifene
vs alendronian was below cost-effectiveness threshold.
CONCLUSIONS: Given the results of the analysis, in
osteoporotic postmenopausal women calcitonin is less
effective and more costly than alendronate and ralox-
ifene. Raloxifene can be considered as cost-effective when
compared with alendronate and within the Polish context
offers substantial beneﬁt at reasonable cost.
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